DNA Test Launched for Laser Eye Surgery Safety
|
By LabMedica International staff writers Posted on 27 May 2014 |

Image: Granular corneal dystrophy (Photo courtesy of Dr. B.H. Feldman).
A genetic test has been introduced that can detect both Avellino Corneal Dystrophy (ACD) and another genetic mutation, Granular Corneal Dystrophy type I (GCD1).
A patient with GCD1 who undergoes vision correction surgery, such as Laser-Assisted in situ Keratomileusis (LASIK), Laser-Assisted Sub-Epithelial Keratectomy (LASEK) or Photorefractive keratectomy (PRK) are at extreme risk of experiencing eventual blindness.
The Avellino DNA Dual Test (Avellino Laboratory; Menlo Park, CA, USA) is able to detect the presence of the genetic mutation, allowing the patient to take precautionary steps to postpone the progression of the condition, including avoiding vision correction surgery. The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries the GCD1 or the GCD2 (ACD) gene mutation. Specifically, the ophthalmologist takes 10 swipes from the inside of each cheek in order to obtain an adequate sample. The sample is then sent to Avellino Lab USA, a Clinical Laboratory Improvement Amendments (CLIA) certified molecular diagnostic testing laboratory. Within 24 to 48 hours, the results are provided to the physician to share with the patient. Avellino Laboratory has branches in North America, Western Europe, and Asia.
Granular Corneal Dystrophy (type 1 and 2) has been diagnosed in patients throughout the world and is one of the more well-known corneal dystrophies related to genetic mutations. Unfortunately, many physicians assume incorrectly that they can diagnose the condition through a visual examination and family history. However, many patients do not show physical symptoms of the condition until later in life. Consequently, relying solely on traditional methods for diagnosis can put patients at risk.
Tom Tooma, MD, founder of NVISION Laser Eye Center, said, (Newport Beach, CA, USA) said, “We have been utilizing the Avellino DNA Test for LASIK Safety since its availability in the United States, and it has been a fantastic tool for both our physicians and patients in increasing their confidence prior to LASIK. Now, with the Avellino DNA Dual Test, patients can go into treatment knowing they are even more protected from adverse outcomes such as loss of vision.” The Avellino DNA Test for LASIK Safety has become the standard of care in Korea with 160 LASIK clinics using this test and in Japan more than 80% of LASIK patients were tested.
Related Links:
Avellino Laboratory
NVISION Laser Eye Center
A patient with GCD1 who undergoes vision correction surgery, such as Laser-Assisted in situ Keratomileusis (LASIK), Laser-Assisted Sub-Epithelial Keratectomy (LASEK) or Photorefractive keratectomy (PRK) are at extreme risk of experiencing eventual blindness.
The Avellino DNA Dual Test (Avellino Laboratory; Menlo Park, CA, USA) is able to detect the presence of the genetic mutation, allowing the patient to take precautionary steps to postpone the progression of the condition, including avoiding vision correction surgery. The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries the GCD1 or the GCD2 (ACD) gene mutation. Specifically, the ophthalmologist takes 10 swipes from the inside of each cheek in order to obtain an adequate sample. The sample is then sent to Avellino Lab USA, a Clinical Laboratory Improvement Amendments (CLIA) certified molecular diagnostic testing laboratory. Within 24 to 48 hours, the results are provided to the physician to share with the patient. Avellino Laboratory has branches in North America, Western Europe, and Asia.
Granular Corneal Dystrophy (type 1 and 2) has been diagnosed in patients throughout the world and is one of the more well-known corneal dystrophies related to genetic mutations. Unfortunately, many physicians assume incorrectly that they can diagnose the condition through a visual examination and family history. However, many patients do not show physical symptoms of the condition until later in life. Consequently, relying solely on traditional methods for diagnosis can put patients at risk.
Tom Tooma, MD, founder of NVISION Laser Eye Center, said, (Newport Beach, CA, USA) said, “We have been utilizing the Avellino DNA Test for LASIK Safety since its availability in the United States, and it has been a fantastic tool for both our physicians and patients in increasing their confidence prior to LASIK. Now, with the Avellino DNA Dual Test, patients can go into treatment knowing they are even more protected from adverse outcomes such as loss of vision.” The Avellino DNA Test for LASIK Safety has become the standard of care in Korea with 160 LASIK clinics using this test and in Japan more than 80% of LASIK patients were tested.
Related Links:
Avellino Laboratory
NVISION Laser Eye Center
Latest Molecular Diagnostics News
- New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
- Blood Immune Cell Analysis Detects Parkinson’s Before Symptoms Appear
- New Diagnostic Marker for Ovarian Cancer to Enable Early Disease Detection

- Urine Test Detects Early Stage Pancreatic Cancer
- Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
- Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients
- Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
- Mitochondrial DNA Mutations from Kidney Stressors Could Predict Future Organ Decline
- Blood Test Could Predict Bariatric Surgery Outcomes in Teenagers
- ctDNA Blood Test to Help Personalize Postsurgical Colon Cancer Treatment
- AI Powered Blood Test Predicts Suicide Risk in Bipolar Patients
- DNA Sensor Enables Molecular Detection from Single Blood Drop
- DNA-Powered Test Accurately Detects E. Coli Lookalike Bacteria
- World’s Fastest DNA Sequencing Technique to Revolutionize NICU Genomic Care
- Blood Test Uses Cell-Free DNA to Detect ALS Faster and More Accurately
- Multi-Cancer Early Detection Blood Test Increases Cancer Detection
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read moreMicrobiology
view channel
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








